Objective-Autosomal recessive hypercholesterolemia is a rare inherited disorder, characterized by extremely high total and low-density lipoprotein cholesterol levels, that has been previously linked to mutations in LDLRAP1. We identified a family with autosomal recessive hypercholesterolemia not explained by mutations in LDLRAP1 or other genes known to cause monogenic hypercholesterolemia. The aim of this study was to identify the molecular pathogenesis of autosomal recessive hypercholesterolemia in this family. Approach and Results-We used exome sequencing to assess all protein-coding regions of the genome in 3 family members and identified a homozygous exon 8 splice junction mutation (c.894G>A, also known as E8SJM) in LIPA that segregated with the diagnosis of hypercholesterolemia. Because homozygosity for mutations in LIPA is known to cause cholesterol ester storage disease, we performed directed follow-up phenotyping by noninvasively measuring hepatic cholesterol content. We observed abnormal hepatic accumulation of cholesterol in the homozygote individuals, supporting the diagnosis of cholesterol ester storage disease. Given previous suggestions of cardiovascular disease risk in heterozygous LIPA mutation carriers, we genotyped E8SJM in >27 000 individuals and found no association with plasma lipid levels or risk of myocardial infarction, confirming a true recessive mode of inheritance.
M onogenic hypercholesterolemia is a disorder of lipid metabolism in which extremely elevated levels of total and low-density lipoprotein cholesterol (LDL-C) are caused by a single gene mutation. Mutations in LDLR, 1 APOB, 2 and PCSK9 3 cause autosomal dominant hypercholesterolemia, a disease affecting ≥1 in 500 individuals. Autosomal recessive hypercholesterolemia occurs much less frequently, estimated to occur in 1:1 000 000 live births, and has been linked to mutations in LDLRAP1. 4 In some families with apparent monogenic hypercholesterolemia, an underlying molecular defect cannot be identified in any of these known genes.
We identified a family with apparent Mendelian inheritance of high LDL-C levels that was not caused by mutations in any of the above genes known to affect LDL-C. The small size of the family pedigree precluded use of traditional linkage mapping. Next-generation sequencing (NGS), a rapid and low-cost method to perform large-scale DNA sequencing, 5 has emerged as an important tool for uncovering the cause of inherited diseases. 6 In this study, we used exome sequencing, a technique in which NGS is used to assess all protein-coding regions of the genome, in 3 individuals from this family to search for a rare genetic variant that cosegregated with high LDL-C levels.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Subject Recruitment
The proband (Figure 1 ; individual II-2) presented to the Lipid Clinic at the Academic Medical Center, University of Amsterdam, The Netherlands, at the age of 23. Her LDL-C level exceeded the 99th percentile when adjusted for age and sex. She had 2 siblings (1 of which was a monozygotic twin), both of whom shared LDL-C levels exceeding the 99th percentile. Her father and mother, a nonconsanguineous union, had LDL-C levels at the 25th and 78th percentile, respectively, when adjusted for age and sex (Figure 1) . The proband and both siblings lacked hepatosplenomegaly on abdominal examination. Based on the pedigree, an autosomal recessive mode of inheritance seemed to be the most likely explanation for the family's phenotype.
Exome Sequencing
To identify the molecular basis of hypercholesterolemia in this family, exome sequencing was performed in the proband, the proband's father, and the proband's brother (Figure 1 ; individuals II-2, I-1, and II-1, respectively). A total of 32 950 014 bases across the exome were targeted, and each sample was sequenced with an average of 126-fold coverage across the target. Across the exome, 82% of targeted bases were covered with >30-fold coverage. This yielded a mean of 36 986 single nucleotide variants per individual. The average ratio of heterozygous to homozygous alleles (1.6) and ratio of transitions to transversions (2.7) per individual were expected and similar to contemporary large-scale population sequencing projects. 
Exome Sequencing Analysis
To exclude genetic variation unlikely to be responsible for this family's hypercholesterolemia, we relied on 3 main assumptions: (1) the causal variant(s) alters the gene's corresponding protein product; (2) the causal variant(s) is inherited in an autosomal recessive fashion; and (3) the causal variant(s) exhibits complete penetrance. For the first assumption, we only included single nucleotide substitutions and short insertions or deletions that were predicted to alter the protein sequence.
We next included either (1) compound heterozygous changes (a heterozygous variant in both affected siblings and the father located in a gene that also contained a separate heterozygous variant in both affected siblings not found in the father) or (2) variants that were homozygous in both affected siblings and heterozygous in the unaffected father. Finally, we excluded variants from further consideration if they were present in the general population at a frequency of >1%, or if they were present in either heterozygous or homozygous form in the exome sequences of 235 individuals with very low LDL-C levels.
After applying this analysis, the number of variants shared among the 3 family members was reduced from 54 301 to 2 candidate single nucleotide substitutions. One was a synonymous variant predicted to alter the splice donor site of the eighth exon in the gene lipase A, lysosomal acid, cholesterol esterase (LIPA; c.894G>A, in the last nucleotide of exon 8), and the other was a missense change predicted to result in the substitution of Alanine for Proline at residue 384 in the gene ATP/GTP binding protein-like 2 (AGBL2).
Because previous reports showed a link between the c.894G>A mutation, also known as the exon 8 splice junction 8 a disorder with mixed hyperlipidemia as part of the phenotypic presentation, we focused on a potential diagnosis of CESD as the most likely cause for this family's apparent autosomal recessive hypercholesterolemia.
Functional Assessment of E8SJM
Sanger sequencing was performed and confirmed the presence of the E8SJM allele in the homozygous state in affected individuals and in the heterozygous state in both unaffected parents. Haplotype analysis revealed that both maternal and paternal E8SJM alleles were on the same haplotype as previously reported for this mutation (haplotype 1 from Fasano et al 9 ). This does not appear to be a result of consanguinity because the proband was found to share 53% and 49% of her exome identical-by-descent with her brother and father, respectively, eliminating cryptic consanguinity. The skipping of exon 8 was confirmed in all individuals carrying the mutated allele ( Figure 2 ).
Although the affected individuals did not present with clinically apparent hepatic disease, given the previous reports linking mutations in LIPA with CESD, we reassessed the affected individuals for the level of hepatic cholesterol ester using magnetic resonance spectroscopy (MRS), a technique 
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shown to correlate well with histological lipid distribution. 10 In individuals II-1, II-2, and II-3, MRS demonstrated a distinct cholesterol peak separate from the larger and expected triglyceride peak at 1.25 ppm. The ratios between triglyceride at 1.25 ppm and cholesterol at 0.9 ppm were 0.57, 0.34, and 0.40 for individuals II-1, II-2, and II-3, respectively, indicating the presence of an excess of hepatic cholesterol deposition (Figure 3) . The elevated cholesterol peak at 0.9 ppm was not identified in individual I-1. Individuals II-1, II-2, and II-3 had normal hepatic size as measured on the MRI portion of the study.
Population Impact of E8SJM
Given previous reports suggesting that serum lipids levels are increased in heterozygous E8SJM carriers, 11 we genotyped the E8SJM variant in 13 194 individuals of European ancestry. Triglyceride, high-density lipoprotein cholesterol, and LDL-C levels were available in 13 194, 13 144, and 12 805 individuals, respectively. In these individuals, the E8SJM was present with an allele frequency of 0.16% and no association was observed with any of these 3 lipid fractions (Table 1) .
Furthermore, to also assess the impact of partial loss of LIPA function on risk for myocardial infarction (MI) or coronary artery disease (CAD) in the population, we genotyped the E8SJM variant in 27 472 individuals of European ancestry (12 747 cases with MI/CAD, 14 725 controls free of MI and CAD). In these individuals, the E8SJM was present with an allele frequency of 0.11% and there was no association of E8SJM with risk for MI or CAD (odds ratio for MI or CAD in carriers=0.85; P=0.6).
Discussion
Traditional Mendelian genetic analyses have relied on positional cloning and sequencing the genetic regions under linked peaks to identify causal defects responsible for monogenic disorders. These techniques are unfortunately of limited use in small families such as the one presented in the current study. NGS, however, now allows for the potential identification of candidate genes underlying Mendelian disorders in families regardless of the pedigree size. In this study, we performed NGS across the exome in 3 individuals from a family with suspected autosomal recessive hypercholesterolemia and identified homozygous E8SJM alleles in LIPA that cosegregated with the clinical diagnosis of hypercholesterolemia.
Lysosomal acid lipase (LAL), encoded by the gene LIPA, is responsible for hydrolyzing cholesterol esters and triglycerides that are delivered to lysosomes. Mutations in LIPA that completely inactivate LAL have previously been identified as the molecular cause of Wolman disease, a rapidly lethal disease of infancy, characterized by hepatosplenomegaly, abdominal distension, adrenal calcification, and steatorrhea with extensive storage of cholesterol esters and triglycerides in the liver, spleen, and other organs in the first weeks of life. 12, 13 A related disorder, CESD, is associated with a less severe phenotype. 14, 15 Characterized by massive hepatic accumulation of cholesterol esters, hepatomegaly, steatosis, and mixed hyperlipidemia, CESD is caused by mutations in LIPA that result in near complete loss of LAL activity with enough residual enzymatic activity to hydrolyze triglycerides but not cholesterol esters.
The identification of homozygous E8SJM alleles in LIPA was surprising in this family because it has been previously identified as a cause of CESD. 16 E8SJM has been shown to cause subtotal loss of gene function resulting in only 2% to 4% normally spliced LIPA mRNA transcripts and LAL activity. 16 Homozygosity for E8SJM has previously been reported in individuals with hepatic disease and mixed hyperlipidemia, characterized by elevated levels of LDL-C and triglyceride with decreased high-density lipoprotein cholesterol levels ( Table 2) .
The homozygous individuals in the current study presented with a very different phenotype and would not have been clinically diagnosed with CESD. Their lipid profile is characterized by extremely elevated LDL-C with normal to high high-density lipoprotein cholesterol and normal triglyceride levels, whereas previously described E8SJM homozygotes have been noted to have increased LDL-C with low highdensity lipoprotein cholesterol and elevated triglyceride levels ( Table 2 ). In addition, the hepatic phenotype in the homozygous individuals from the current study appears to consist of only a subtle elevation in alanine aminotransferase (Table 2) Figure 3 . Water suppressed magnetic resonance spectroscopy spectra demonstrating hepatic cholesterol deposition in homozygous carriers of LIPA exon 8 splice junction mutation (E8SJM). R indicates ratio between peaks at 1.25 and 0.9 ppm. A, Individual I-1, the unaffected father of the proband, demonstrates a normal ratio. B to D, Individuals II-2, II-3, and II-1, respectively, demonstrate elevated ratios. Given the previous associations between LIPA E8SJM and CESD (for homozygous carriers) and polygenic hypercholesterolemia and potentially increased risk of MI/CAD (for heterozygous carriers), 11 we performed directed phenotypic and genetic follow-up analyses to address 2 questions: (1) Do the homozygous carriers within this pedigree have hepatic hallmarks of CESD?; and (2) Are the heterozygous parents at increased risk for MI/CAD? Using noninvasive hepatic MRS, we demonstrated the presence of abnormal quantities of hepatic cholesterol in the homozygous E8SJM carriers of this family. This finding is entirely consistent with previously reported hepatic MRS findings in patients with LAL deficiency (previously reported MRS ratios, 0.24-0.5) 18 and confirms the diagnosis of CESD in the 3 offspring. A liver biopsy was not thought to be clinically indicated given the absence of increased transaminase levels combined with previous reports surrounding the causal role of LIPA E8SJM in CESD and the confirmatory MRS findings. Although a seemingly subtle distinction, this diagnosis is clinically important because the offspring should be followed for the progression of hepatic disease and may be potential candidates in the future for enzyme replacement therapy that is currently in development. 19 In addition, this finding illustrates that CESD may have a more variable phenotypic presentation than previously appreciated.
To assess the potential of increased cardiovascular disease risk in the heterozygous parents, we genotyped LIPA E8SJM in the population. The population frequency of LIPA E8SJM has previously been estimated to be between 0.21% and 0.25% in individuals of European descent 20, 21 and has been associated with a polygenic hypercholesterolemia phenotype, 11 prompting the hypothesis that it may be associated with increased risk of MI/CAD. We now firmly establish that this variant is rarer than previously estimated (allele frequency=0.11%). We consider our estimate of the carrier frequency for European individuals to be more accurate than previous reports given the larger numbers of individuals assessed (27 472 in the current study compared with 4112 in a previous report). 21 In this large genetic study, we observed no association of heterozygosity with plasma lipid levels or risk for MI/CAD. Although we cannot definitively exclude a weak association with MI/CAD or serum lipid levels, we had 93% power to detect a 2-fold increased risk of MI/CAD at an α of 0.05 and 94% power to detect a variant explaining 0.1% of the phenotypic variance in LDL-C at an α of 0.05. These findings suggest that the E8SJM acts in a truly recessive fashion and that heterozygous loss of function does not result in a distinct lipid or MI phenotype.
It is uncertain why the presentation of CESD in this family differed from those described in previous reports. The E8SJM in this family occurs on the same haplotype as previously reported for this mutation, supporting a common founder, ancestor for this mutation and suggesting that the milder-thanexpected phenotype is not explained by a simple difference of local genetic background in LIPA. In addition to the E8SJM in LIPA, we identified rare homozygous alleles in AGBL2 carried by all 3 affected offspring. At this time it is unclear what, if any, phenotypic effect this confers. There may be a genetic factor (in AGBL2 or elsewhere) conferring a protective hepatic effect; however, given the lack of family members with hepatic disease as a comparator, we are underpowered to discover such a variant.
In summary, we report homozygosity for E8SJM in LIPA as a cause of clinically unapparent CESD presenting as autosomal recessive hypercholesterolemia. The discovery of E8SJM in LIPA in this family highlights both the blessing and the curse of using NGS in genetic discovery studies; along with the potential unbiased discovery of the causal variant ALT indicates alanine aminotransferase (upper limit of normal in current study, 34 IU/L); AST, aspartate aminotransferase (upper limit of normal in current study, 40 IU/L); E8SJM, exon 8 splice junction mutation; HDL-C, high-density lipoprotein cholesterol; HM, hepatomegaly; HSM, hepatosplenomegaly; ID, individual ID from family pedigree ( Figure 1) ; LDL-C, low-density lipoprotein cholesterol; N/A, not available; TC, total cholesterol; TG, triglycerides; and ULN, upper limit of normal.
by guest on April 8, 2017 http://atvb.ahajournals.org/ Downloaded from December 2013 comes tens of thousands of additional variants unrelated to the phenotype of interest and the possibility of unexpected findings. We suggest integrating Mendelian and population genetics with directed clinical testing as a powerful way to discern signal from noise in the next generation of genetic discovery studies. 
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